1 Study Coverage 1.1 Neuroendocrine Tumors (NETs) Treatment Product Introduction 1.2 Market by Type 1.2.1 Global Neuroendocrine Tumors (NETs) Treatment Market Size Growth Rate by Type 1.2.2 Somatostatin Analogs (SSAs) 1.2.3 Targeted Therapy 1.2.4 Other 1.3 Market by Application 1.3.1 Global Neuroendocrine Tumors (NETs) Treatment Market Size Growth Rate by Application 1.3.2 Hospitals 1.3.3 Clinics 1.3.4 Other 1.4 Study Objectives 1.5 Years Considered 2 Executive Summary 2.1 Global Neuroendocrine Tumors (NETs) Treatment Market Size, Estimates and Forecasts 2.1.1 Global Neuroendocrine Tumors (NETs) Treatment Revenue 2016-2027 2.1.2 Global Neuroendocrine Tumors (NETs) Treatment Sales 2016-2027 2.2 Global Neuroendocrine Tumors (NETs) Treatment, Market Size by Region: 2016 VS 2021 VS 2027 2.3 Neuroendocrine Tumors (NETs) Treatment Historical Market Size by Region (2016-2021) 2.3.1 Global Neuroendocrine Tumors (NETs) Treatment Retrospective Market Scenario in Sales by Region: 2016-2021 2.3.2 Global Neuroendocrine Tumors (NETs) Treatment Retrospective Market Scenario in Revenue by Region: 2016-2021 2.4 Neuroendocrine Tumors (NETs) Treatment Market Estimates and Projections by Region (2022-2027) 2.4.1 Global Neuroendocrine Tumors (NETs) Treatment Sales Forecast by Region (2022-2027) 2.4.2 Global Neuroendocrine Tumors (NETs) Treatment Revenue Forecast by Region (2022-2027) 3 Global Neuroendocrine Tumors (NETs) Treatment Competitor Landscape by Players 3.1 Global Top Neuroendocrine Tumors (NETs) Treatment Manufacturers by Sales 3.1.1 Global Neuroendocrine Tumors (NETs) Treatment Sales by Manufacturer (2016-2021) 3.1.2 Global Neuroendocrine Tumors (NETs) Treatment Sales Market Share by Manufacturer (2016-2021) 3.2 Global Top Neuroendocrine Tumors (NETs) Treatment Manufacturers by Revenue 3.2.1 Key Neuroendocrine Tumors (NETs) Treatment Manufacturers Covered: Ranking by Revenue 3.2.2 Global Neuroendocrine Tumors (NETs) Treatment Revenue by Manufacturers (2016-2021) 3.2.3 Global Neuroendocrine Tumors (NETs) Treatment Revenue Share by Manufacturers (2016-2021) 3.2.4 Global Neuroendocrine Tumors (NETs) Treatment Market Concentration Ratio (CR5 and HHI) (2016-2021) 3.2.5 Global Top 10 and Top 5 Companies by Neuroendocrine Tumors (NETs) Treatment Revenue in 2020 3.2.6 Global Neuroendocrine Tumors (NETs) Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3) 3.3 Global Neuroendocrine Tumors (NETs) Treatment Price by Manufacturers 3.4 Global Neuroendocrine Tumors (NETs) Treatment Manufacturing Base Distribution, Product Types 3.4.1 Neuroendocrine Tumors (NETs) Treatment Manufacturers Manufacturing Base Distribution, Headquarters 3.4.2 Manufacturers Neuroendocrine Tumors (NETs) Treatment Product Type 3.4.3 Date of International Manufacturers Enter into Neuroendocrine Tumors (NETs) Treatment Market 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans 4 Breakdown Data by Type (2016-2027) 4.1 Global Neuroendocrine Tumors (NETs) Treatment Market Size by Type (2016-2021) 4.1.1 Global Neuroendocrine Tumors (NETs) Treatment Sales by Type (2016-2021) 4.1.2 Global Neuroendocrine Tumors (NETs) Treatment Revenue by Type (2016-2021) 4.1.3 Neuroendocrine Tumors (NETs) Treatment Average Selling Price (ASP) by Type (2016-2021) 4.2 Global Neuroendocrine Tumors (NETs) Treatment Market Size Forecast by Type (2022-2027) 4.2.1 Global Neuroendocrine Tumors (NETs) Treatment Sales Forecast by Type (2022-2027) 4.2.2 Global Neuroendocrine Tumors (NETs) Treatment Revenue Forecast by Type (2022-2027) 4.2.3 Neuroendocrine Tumors (NETs) Treatment Average Selling Price (ASP) Forecast by Type (2022-2027) 5 Breakdown Data by Application (2016-2027) 5.1 Global Neuroendocrine Tumors (NETs) Treatment Market Size by Application (2016-2021) 5.1.1 Global Neuroendocrine Tumors (NETs) Treatment Sales by Application (2016-2021) 5.1.2 Global Neuroendocrine Tumors (NETs) Treatment Revenue by Application (2016-2021) 5.1.3 Neuroendocrine Tumors (NETs) Treatment Price by Application (2016-2021) 5.2 Neuroendocrine Tumors (NETs) Treatment Market Size Forecast by Application (2022-2027) 5.2.1 Global Neuroendocrine Tumors (NETs) Treatment Sales Forecast by Application (2022-2027) 5.2.2 Global Neuroendocrine Tumors (NETs) Treatment Revenue Forecast by Application (2022-2027) 5.2.3 Global Neuroendocrine Tumors (NETs) Treatment Price Forecast by Application (2022-2027) 6 China by Players, Type and Application 6.1 China Neuroendocrine Tumors (NETs) Treatment Market Size YoY Growth 2016-2027 6.1.1 China Neuroendocrine Tumors (NETs) Treatment Sales YoY Growth 2016-2027 6.1.2 China Neuroendocrine Tumors (NETs) Treatment Revenue YoY Growth 2016-2027 6.1.3 China Neuroendocrine Tumors (NETs) Treatment Market Share in Global Market 2016-2027 6.2 China Neuroendocrine Tumors (NETs) Treatment Market Size by Players (International and Local Players) 6.2.1 China Top Neuroendocrine Tumors (NETs) Treatment Players by Sales (2016-2021) 6.2.2 China Top Neuroendocrine Tumors (NETs) Treatment Players by Revenue (2016-2021) 6.3 China Neuroendocrine Tumors (NETs) Treatment Historic Market Review by Type (2016-2021) 6.3.1 China Neuroendocrine Tumors (NETs) Treatment Sales Market Share by Type (2016-2021) 6.3.2 China Neuroendocrine Tumors (NETs) Treatment Revenue Market Share by Type (2016-2021) 6.3.3 China Neuroendocrine Tumors (NETs) Treatment Price by Type (2016-2021) 6.4 China Neuroendocrine Tumors (NETs) Treatment Market Estimates and Forecasts by Type (2022-2027) 6.4.1 China Neuroendocrine Tumors (NETs) Treatment Sales Forecast by Type (2022-2027) 6.4.2 China Neuroendocrine Tumors (NETs) Treatment Revenue Forecast by Type (2022-2027) 6.4.3 China Neuroendocrine Tumors (NETs) Treatment Price Forecast by Type (2022-2027) 6.5 China Neuroendocrine Tumors (NETs) Treatment Historic Market Review by Application (2016-2021) 6.5.1 China Neuroendocrine Tumors (NETs) Treatment Sales Market Share by Application (2016-2021) 6.5.2 China Neuroendocrine Tumors (NETs) Treatment Revenue Market Share by Application (2016-2021) 6.5.3 China Neuroendocrine Tumors (NETs) Treatment Price by Application (2016-2021) 6.6 China Neuroendocrine Tumors (NETs) Treatment Market Estimates and Forecasts by Application (2022-2027) 6.6.1 China Neuroendocrine Tumors (NETs) Treatment Sales Forecast by Application (2022-2027) 6.6.2 China Neuroendocrine Tumors (NETs) Treatment Revenue Forecast by Application (2022-2027) 6.6.3 China Neuroendocrine Tumors (NETs) Treatment Price Forecast by Application (2022-2027) 7 North America 7.1 North America Neuroendocrine Tumors (NETs) Treatment Market Size YoY Growth 2016-2027 7.2 North America Neuroendocrine Tumors (NETs) Treatment Market Facts & Figures by Country 7.2.1 North America Neuroendocrine Tumors (NETs) Treatment Sales by Country (2016-2021) 7.2.2 North America Neuroendocrine Tumors (NETs) Treatment Revenue by Country (2016-2021) 7.2.3 U.S. 7.2.4 Canada 8 Asia Pacific 8.1 Asia Pacific Neuroendocrine Tumors (NETs) Treatment Market Size YoY Growth 2016-2027 8.2 Asia Pacific Neuroendocrine Tumors (NETs) Treatment Market Facts & Figures by Region 8.2.1 Asia Pacific Neuroendocrine Tumors (NETs) Treatment Sales by Region (2016-2021) 8.2.2 Asia Pacific Neuroendocrine Tumors (NETs) Treatment Revenue by Region (2016-2021) 8.2.3 China 8.2.4 Japan 8.2.5 South Korea 8.2.6 India 8.2.7 Australia 8.2.8 Australia 8.2.9 Indonesia 8.2.10 Thailand 8.2.11 Malaysia 8.2.12 Philippines 8.2.13 Vietnam 9 Europe 9.1 Europe Neuroendocrine Tumors (NETs) Treatment Market Size YoY Growth 2016-2027 9.2 Europe Neuroendocrine Tumors (NETs) Treatment Market Facts & Figures by Country 9.2.1 Europe Neuroendocrine Tumors (NETs) Treatment Sales by Country (2016-2021) 9.2.2 Europe Neuroendocrine Tumors (NETs) Treatment Revenue by Country (2016-2021) 9.2.3 Germany 9.2.4 France 9.2.5 U.K. 9.2.6 Italy 10 Latin America 10.1 Latin America Neuroendocrine Tumors (NETs) Treatment Market Size YoY Growth 2016-2027 10.2 Latin America Neuroendocrine Tumors (NETs) Treatment Market Facts & Figures by Country 10.2.1 Latin America Neuroendocrine Tumors (NETs) Treatment Sales by Country (2016-2021) 10.2.2 Latin America Neuroendocrine Tumors (NETs) Treatment Revenue by Country (2016-2021) 10.2.3 Mexico 10.2.4 Brazil 10.2.5 Argentina 11 Middle East and Africa 11.1 Middle East and Africa Neuroendocrine Tumors (NETs) Treatment Market Size YoY Growth 2016-2027 11.2 Middle East and Africa Neuroendocrine Tumors (NETs) Treatment Market Facts & Figures by Country 11.2.1 Middle East and Africa Neuroendocrine Tumors (NETs) Treatment Sales by Country (2016-2021) 11.2.2 Middle East and Africa Neuroendocrine Tumors (NETs) Treatment Revenue by Country (2016-2021) 11.2.3 Turkey 11.2.4 Saudi Arabia 11.2.5 U.A.E 12 Company Profiles 12.1 Advanced Accelerator Applications 12.1.1 Advanced Accelerator Applications Corporation Information 12.1.2 Advanced Accelerator Applications Description and Business Overview 12.1.3 Advanced Accelerator Applications Neuroendocrine Tumors (NETs) Treatment Sales, Revenue and Gross Margin (2016-2021) 12.1.4 Advanced Accelerator Applications Neuroendocrine Tumors (NETs) Treatment Products Offered 12.1.5 Advanced Accelerator Applications Recent Development 12.2 AVEO Oncology 12.2.1 AVEO Oncology Corporation Information 12.2.2 AVEO Oncology Description and Business Overview 12.2.3 AVEO Oncology Neuroendocrine Tumors (NETs) Treatment Sales, Revenue and Gross Margin (2016-2021) 12.2.4 AVEO Oncology Neuroendocrine Tumors (NETs) Treatment Products Offered 12.2.5 AVEO Oncology Recent Development 12.3 Boehringer Ingelheim International 12.3.1 Boehringer Ingelheim International Corporation Information 12.3.2 Boehringer Ingelheim International Description and Business Overview 12.3.3 Boehringer Ingelheim International Neuroendocrine Tumors (NETs) Treatment Sales, Revenue and Gross Margin (2016-2021) 12.3.4 Boehringer Ingelheim International Neuroendocrine Tumors (NETs) Treatment Products Offered 12.3.5 Boehringer Ingelheim International Recent Development 12.4 Hutchison MediPharma Limited 12.4.1 Hutchison MediPharma Limited Corporation Information 12.4.2 Hutchison MediPharma Limited Description and Business Overview 12.4.3 Hutchison MediPharma Limited Neuroendocrine Tumors (NETs) Treatment Sales, Revenue and Gross Margin (2016-2021) 12.4.4 Hutchison MediPharma Limited Neuroendocrine Tumors (NETs) Treatment Products Offered 12.4.5 Hutchison MediPharma Limited Recent Development 12.5 IpsenPharma 12.5.1 IpsenPharma Corporation Information 12.5.2 IpsenPharma Description and Business Overview 12.5.3 IpsenPharma Neuroendocrine Tumors (NETs) Treatment Sales, Revenue and Gross Margin (2016-2021) 12.5.4 IpsenPharma Neuroendocrine Tumors (NETs) Treatment Products Offered 12.5.5 IpsenPharma Recent Development 12.6 Novartis AG 12.6.1 Novartis AG Corporation Information 12.6.2 Novartis AG Description and Business Overview 12.6.3 Novartis AG Neuroendocrine Tumors (NETs) Treatment Sales, Revenue and Gross Margin (2016-2021) 12.6.4 Novartis AG Neuroendocrine Tumors (NETs) Treatment Products Offered 12.6.5 Novartis AG Recent Development 12.7 Pfizer, Inc 12.7.1 Pfizer, Inc Corporation Information 12.7.2 Pfizer, Inc Description and Business Overview 12.7.3 Pfizer, Inc Neuroendocrine Tumors (NETs) Treatment Sales, Revenue and Gross Margin (2016-2021) 12.7.4 Pfizer, Inc Neuroendocrine Tumors (NETs) Treatment Products Offered 12.7.5 Pfizer, Inc Recent Development 12.8 Progenics Pharmaceuticals 12.8.1 Progenics Pharmaceuticals Corporation Information 12.8.2 Progenics Pharmaceuticals Description and Business Overview 12.8.3 Progenics Pharmaceuticals Neuroendocrine Tumors (NETs) Treatment Sales, Revenue and Gross Margin (2016-2021) 12.8.4 Progenics Pharmaceuticals Neuroendocrine Tumors (NETs) Treatment Products Offered 12.8.5 Progenics Pharmaceuticals Recent Development 12.11 Advanced Accelerator Applications 12.11.1 Advanced Accelerator Applications Corporation Information 12.11.2 Advanced Accelerator Applications Description and Business Overview 12.11.3 Advanced Accelerator Applications Neuroendocrine Tumors (NETs) Treatment Sales, Revenue and Gross Margin (2016-2021) 12.11.4 Advanced Accelerator Applications Neuroendocrine Tumors (NETs) Treatment Products Offered 12.11.5 Advanced Accelerator Applications Recent Development 13 Market Opportunities, Challenges, Risks and Influences Factors Analysis 13.1 Neuroendocrine Tumors (NETs) Treatment Industry Trends 13.2 Neuroendocrine Tumors (NETs) Treatment Market Drivers 13.3 Neuroendocrine Tumors (NETs) Treatment Market Challenges 13.4 Neuroendocrine Tumors (NETs) Treatment Market Restraints 14 Value Chain and Sales Channels Analysis 14.1 Value Chain Analysis 14.2 Neuroendocrine Tumors (NETs) Treatment Customers 14.3 Sales Channels Analysis 14.3.1 Sales Channels 14.3.2 Distributors 15 Research Findings and Conclusion 16 Appendix 16.1 Research Methodology 16.1.1 Methodology/Research Approach 16.1.2 Data Source 16.2 Author Details 16.3 Disclaimer

List of Tables Table 1. Global Neuroendocrine Tumors (NETs) Treatment Market Size Growth Rate by Type, 2016 VS 2021 VS 2027 (US$ Million) Table 2. Major Manufacturers of Somatostatin Analogs (SSAs) Table 3. Major Manufacturers of Targeted Therapy Table 4. Major Manufacturers of Other Table 5. Global Neuroendocrine Tumors (NETs) Treatment Market Size Growth Rate by Application (2021-2027) & (K Pcs) Table 6. Global Neuroendocrine Tumors (NETs) Treatment Market Size by Region (K Pcs) & (US$ Million), 2016 VS 2021 VS 2027 Table 7. Global Neuroendocrine Tumors (NETs) Treatment Sales by Regions (2016-2021) & (K Pcs) Table 8. Global Neuroendocrine Tumors (NETs) Treatment Sales Market Share by Regions (2016-2021) Table 9. Global Neuroendocrine Tumors (NETs) Treatment Revenue by Regions (2016-2021) & (US$ Million) Table 10. Global Neuroendocrine Tumors (NETs) Treatment Sales Forecast by Region (2022-2027) & (K Pcs) Table 11. Global Neuroendocrine Tumors (NETs) Treatment Sales Market Share Forecast by Region (2022-2027) Table 12. Global Neuroendocrine Tumors (NETs) Treatment Revenue Forecast by Region (2022-2027) & (US$ Million) Table 13. Global Neuroendocrine Tumors (NETs) Treatment Revenue Market Share Forecast by Region (2022-2027) Table 14. Global Neuroendocrine Tumors (NETs) Treatment Sales by Manufacturers (2016-2021) (K Pcs) Table 15. Global Neuroendocrine Tumors (NETs) Treatment Sales Share by Manufacturers (2016-2021) Table 16. Ranking of Global Top Neuroendocrine Tumors (NETs) Treatment Manufacturers by Revenue (US$ Million) in 2020 Table 17. Neuroendocrine Tumors (NETs) Treatment Revenue by Manufacturers (2016-2021) (US$ Million) Table 18. Neuroendocrine Tumors (NETs) Treatment Revenue Share by Manufacturers (2016-2021) Table 19. Global Neuroendocrine Tumors (NETs) Treatment Manufacturers Market Concentration Ratio (CR5 and HHI) & (2016-2021) Table 20. Global Neuroendocrine Tumors (NETs) Treatment by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Neuroendocrine Tumors (NETs) Treatment as of 2020) Table 21. Key Manufacturers Neuroendocrine Tumors (NETs) Treatment Price (2016-2021) (USD/Pcs) Table 22. Neuroendocrine Tumors (NETs) Treatment Manufacturers Manufacturing Base Distribution and Headquarters Table 23. Manufacturers Neuroendocrine Tumors (NETs) Treatment Product Type Table 24. Date of International Manufacturers Enter into Neuroendocrine Tumors (NETs) Treatment Market Table 25. Manufacturers Mergers & Acquisitions, Expansion Plans Table 26. Global Neuroendocrine Tumors (NETs) Treatment Sales by Type (2016-2021) (K Pcs) Table 27. Global Neuroendocrine Tumors (NETs) Treatment Sales Share by Type (2016-2021) Table 28. Global Neuroendocrine Tumors (NETs) Treatment Revenue by Type (2016-2021) (US$ Million) Table 29. Global Neuroendocrine Tumors (NETs) Treatment Revenue Share by Type (2016-2021) Table 30. Neuroendocrine Tumors (NETs) Treatment Average Selling Price (ASP) by Type (2016-2021) & (USD/Pcs) Table 31. Global Neuroendocrine Tumors (NETs) Treatment Sales Forecast by Type (2022-2027) & (K Pcs) Table 32. Global Neuroendocrine Tumors (NETs) Treatment Sales Market Share Forecast by Type (2022-2027) Table 33. Global Neuroendocrine Tumors (NETs) Treatment Revenue Forecast V (2022-2027) & (US$ Million) Table 34. Global Neuroendocrine Tumors (NETs) Treatment Revenue Market Share Forecast by Type (2022-2027) Table 35. Global Neuroendocrine Tumors (NETs) Treatment Average Selling Price (ASP) Forecast by Type (2022-2027) & (USD/Pcs) Table 36. Global Neuroendocrine Tumors (NETs) Treatment Sales by Application (2016-2021) (K Pcs) Table 37. Global Neuroendocrine Tumors (NETs) Treatment Sales Share by Application (2016-2021) Table 38. Global Neuroendocrine Tumors (NETs) Treatment Revenue by Application (2016-2021) (US$ Million) Table 39. Global Neuroendocrine Tumors (NETs) Treatment Revenue Share by Application (2016-2021) Table 40. Neuroendocrine Tumors (NETs) Treatment Average Selling Price (ASP) by Application (2016-2021) & (USD/Pcs) Table 41. Global Neuroendocrine Tumors (NETs) Treatment Sales Forecast by Application (2022-2027) & (K Pcs) Table 42. Global Neuroendocrine Tumors (NETs) Treatment Sales Market Share Forecast by Application (2022-2027) Table 43. Global Neuroendocrine Tumors (NETs) Treatment Revenue Forecast by Application (2022-2027) & (US$ Million) Table 44. Global Neuroendocrine Tumors (NETs) Treatment Revenue Market Share Forecast by Application (2022-2027) Table 45. Global Neuroendocrine Tumors (NETs) Treatment Average Selling Price (ASP) Forecast by Application (2022-2027) & (USD/Pcs) Table 46. China Neuroendocrine Tumors (NETs) Treatment Sales (K Pcs) of Key Companies (2016-2021) Table 47. China Neuroendocrine Tumors (NETs) Treatment Sales Share by Company (2016-2021) Table 48. China Neuroendocrine Tumors (NETs) Treatment Revenue (US$ Million) by Company (2016-2021) Table 49. China Neuroendocrine Tumors (NETs) Treatment Revenue Share by Company (2016-2021) Table 50. China Neuroendocrine Tumors (NETs) Treatment Sales (K Pcs) by Type (2016-2021) Table 51. China Neuroendocrine Tumors (NETs) Treatment Sales Share by Type (2016-2021) Table 52. China Neuroendocrine Tumors (NETs) Treatment Revenue (US$ Million) Market Share by Type (2016-2021) Table 53. China Neuroendocrine Tumors (NETs) Treatment Price (USD/Pcs) by Type (2016-2021) Table 54. China Neuroendocrine Tumors (NETs) Treatment Sales (K Pcs) by Type (2022-2027) Table 55. China Neuroendocrine Tumors (NETs) Treatment Sales Share by Type (2022-2027) Table 56. China Neuroendocrine Tumors (NETs) Treatment Revenue (US$ Million) Market Share by Type (2022-2027) Table 57. China Neuroendocrine Tumors (NETs) Treatment Revenue Share by Type (2022-2027) Table 58. China Neuroendocrine Tumors (NETs) Treatment Price (USD/Pcs) by Type (2022-2027) Table 59. China Neuroendocrine Tumors (NETs) Treatment Sales (K Pcs) by Application (2016-2021) Table 60. China Neuroendocrine Tumors (NETs) Treatment Sales Share by Application (2016-2021) Table 61. China Neuroendocrine Tumors (NETs) Treatment Revenue (US$ Million) Market Share by Application (2016-2021) Table 62. China Neuroendocrine Tumors (NETs) Treatment Price (USD/Pcs) by Application (2016-2021) Table 63. China Neuroendocrine Tumors (NETs) Treatment Sales (K Pcs) by Application (2022-2027) Table 64. China Neuroendocrine Tumors (NETs) Treatment Sales Share by Application (2022-2027) Table 65. China Neuroendocrine Tumors (NETs) Treatment Revenue (US$ Million) Market Share by Application (2022-2027) Table 66. China Neuroendocrine Tumors (NETs) Treatment Revenue Share by Application (2022-2027) Table 67. China Neuroendocrine Tumors (NETs) Treatment Price (USD/Pcs) by Application (2022-2027) Table 68. North America Neuroendocrine Tumors (NETs) Treatment Sales by Country (2016-2021) & (K Pcs) Table 69. North America Neuroendocrine Tumors (NETs) Treatment Sales Market Share by Country (2016-2021) Table 70. North America Neuroendocrine Tumors (NETs) Treatment Revenue by Country (2016-2021) & (US$ Million) Table 71. North America Neuroendocrine Tumors (NETs) Treatment Revenue Market Share by Country (2016-2021) Table 72. Asia Pacific Neuroendocrine Tumors (NETs) Treatment Sales by Region (2016-2021) & (K Pcs) Table 73. Asia Pacific Neuroendocrine Tumors (NETs) Treatment Sales Market Share by Region (2016-2021) Table 74. Asia Pacific Neuroendocrine Tumors (NETs) Treatment Revenue by Region (2016-2021) & (US$ Million) Table 75. Asia Pacific Neuroendocrine Tumors (NETs) Treatment Revenue Market Share by Region (2016-2021) Table 76. Europe Neuroendocrine Tumors (NETs) Treatment Sales by Country (2016-2021) & (K Pcs) Table 77. Europe Neuroendocrine Tumors (NETs) Treatment Sales Market Share by Country (2016-2021) Table 78. Europe Neuroendocrine Tumors (NETs) Treatment Revenue by Country (2016-2021) & (US$ Million) Table 79. Europe Neuroendocrine Tumors (NETs) Treatment Revenue Market Share by Country (2016-2021) Table 80. Latin America Neuroendocrine Tumors (NETs) Treatment Sales by Country (2016-2021) & (K Pcs) Table 81. Latin America Neuroendocrine Tumors (NETs) Treatment Sales Market Share by Country (2016-2021) Table 82. Latin Americaa Neuroendocrine Tumors (NETs) Treatment Revenue by Country (2016-2021) & (US$ Million) Table 83. Latin America Neuroendocrine Tumors (NETs) Treatment Revenue Market Share by Country (2016-2021) Table 84. Middle East and Africa Neuroendocrine Tumors (NETs) Treatment Sales by Country (2016-2021) & (K Pcs) Table 85. Middle East and Africa Neuroendocrine Tumors (NETs) Treatment Sales Market Share by Country (2016-2021) Table 86. Middle East and Africa Neuroendocrine Tumors (NETs) Treatment Revenue by Country (2016-2021) & (US$ Million) Table 87. Middle East and Africa Neuroendocrine Tumors (NETs) Treatment Revenue Market Share by Country (2016-2021) Table 88. Advanced Accelerator Applications Corporation Information Table 89. Advanced Accelerator Applications Description and Business Overview Table 90. Advanced Accelerator Applications Neuroendocrine Tumors (NETs) Treatment Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2016-2021) Table 91. Advanced Accelerator Applications Neuroendocrine Tumors (NETs) Treatment Product Table 92. Advanced Accelerator Applications Recent Development Table 93. AVEO Oncology Corporation Information Table 94. AVEO Oncology Description and Business Overview Table 95. AVEO Oncology Neuroendocrine Tumors (NETs) Treatment Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2016-2021) Table 96. AVEO Oncology Product Table 97. AVEO Oncology Recent Development Table 98. Boehringer Ingelheim International Corporation Information Table 99. Boehringer Ingelheim International Description and Business Overview Table 100. Boehringer Ingelheim International Neuroendocrine Tumors (NETs) Treatment Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2016-2021) Table 101. Boehringer Ingelheim International Product Table 102. Boehringer Ingelheim International Recent Development Table 103. Hutchison MediPharma Limited Corporation Information Table 104. Hutchison MediPharma Limited Description and Business Overview Table 105. Hutchison MediPharma Limited Neuroendocrine Tumors (NETs) Treatment Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2016-2021) Table 106. Hutchison MediPharma Limited Product Table 107. Hutchison MediPharma Limited Recent Development Table 108. IpsenPharma Corporation Information Table 109. IpsenPharma Description and Business Overview Table 110. IpsenPharma Neuroendocrine Tumors (NETs) Treatment Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2016-2021) Table 111. IpsenPharma Product Table 112. IpsenPharma Recent Development Table 113. Novartis AG Corporation Information Table 114. Novartis AG Description and Business Overview Table 115. Novartis AG Neuroendocrine Tumors (NETs) Treatment Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2016-2021) Table 116. Novartis AG Product Table 117. Novartis AG Recent Development Table 118. Pfizer, Inc Corporation Information Table 119. Pfizer, Inc Description and Business Overview Table 120. Pfizer, Inc Neuroendocrine Tumors (NETs) Treatment Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2016-2021) Table 121. Pfizer, Inc Product Table 122. Pfizer, Inc Recent Development Table 123. Progenics Pharmaceuticals Corporation Information Table 124. Progenics Pharmaceuticals Description and Business Overview Table 125. Progenics Pharmaceuticals Neuroendocrine Tumors (NETs) Treatment Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2016-2021) Table 126. Progenics Pharmaceuticals Product Table 127. Progenics Pharmaceuticals Recent Development Table 128. Neuroendocrine Tumors (NETs) Treatment Market Trends Table 129. Neuroendocrine Tumors (NETs) Treatment Market Drivers Table 130. Neuroendocrine Tumors (NETs) Treatment Market Challenges Table 131. Neuroendocrine Tumors (NETs) Treatment Market Restraints Table 132. Neuroendocrine Tumors (NETs) Treatment Customers List Table 133. Neuroendocrine Tumors (NETs) Treatment Distributors List Table 134. Research Programs/Design for This Report Table 135. Key Data Information from Secondary Sources Table 136. Key Data Information from Primary Sources List of Figures Figure 1. Neuroendocrine Tumors (NETs) Treatment Product Picture Figure 2. Global Neuroendocrine Tumors (NETs) Treatment Sales Market Share by Type in 2020 & 2027 Figure 3. Somatostatin Analogs (SSAs) Product Picture Figure 4. Targeted Therapy Product Picture Figure 5. Other Product Picture Figure 6. Global Neuroendocrine Tumors (NETs) Treatment Sales Market Share by Application in 2020 & 2027 Figure 7. Hospitals Figure 8. Clinics Figure 9. Other Figure 10. Neuroendocrine Tumors (NETs) Treatment Report Years Considered Figure 11. Global Neuroendocrine Tumors (NETs) Treatment Market Size, (US$ Million), 2016 VS 2021 VS 2027 Figure 12. Global Neuroendocrine Tumors (NETs) Treatment Market Size 2016-2027 (US$ Million) Figure 13. Global Neuroendocrine Tumors (NETs) Treatment Sales 2016-2027 (K Pcs) Figure 14. Global Neuroendocrine Tumors (NETs) Treatment Market Size Market Share by Region: 2021 Versus 2027 Figure 15. Global Neuroendocrine Tumors (NETs) Treatment Sales Market Share by Region (2016-2021) Figure 16. Global Neuroendocrine Tumors (NETs) Treatment Sales Market Share by Region in 2020 Figure 17. Global Neuroendocrine Tumors (NETs) Treatment Revenue Market Share by Region (2016-2021) Figure 18. Global Neuroendocrine Tumors (NETs) Treatment Revenue Market Share by Region in 2020 Figure 19. Global Neuroendocrine Tumors (NETs) Treatment Sales Share by Manufacturer in 2020 Figure 20. The Top 10 and 5 Players Market Share by Neuroendocrine Tumors (NETs) Treatment Revenue in 2020 Figure 21. Neuroendocrine Tumors (NETs) Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2016 VS 2020 Figure 22. Global Neuroendocrine Tumors (NETs) Treatment Sales Market Share by Type (2016-2021) Figure 23. Global Neuroendocrine Tumors (NETs) Treatment Sales Market Share by Type in 2020 Figure 24. Global Neuroendocrine Tumors (NETs) Treatment Revenue Market Share by Type (2016-2021) Figure 25. Global Neuroendocrine Tumors (NETs) Treatment Revenue Market Share by Type in 2020 Figure 26. Global Neuroendocrine Tumors (NETs) Treatment Sales Market Share by Application (2016-2021) Figure 27. Global Neuroendocrine Tumors (NETs) Treatment Sales Market Share by Application in 2020 Figure 28. Global Neuroendocrine Tumors (NETs) Treatment Revenue Market Share by Application (2016-2021) Figure 29. Global Neuroendocrine Tumors (NETs) Treatment Revenue Market Share by Application in 2020 Figure 30. China Neuroendocrine Tumors (NETs) Treatment Sales Growth Rate 2016-2027 (K Pcs) Figure 31. China Neuroendocrine Tumors (NETs) Treatment Revenue Growth Rate 2016-2027 (US$ Million) Figure 32. China Neuroendocrine Tumors (NETs) Treatment Market Share in Global Market 2016-2027 Figure 33. China 5 and 10 Largest Neuroendocrine Tumors (NETs) Treatment Players Market Share by Revenue in Neuroendocrine Tumors (NETs) Treatment in 2020 Figure 34. China Neuroendocrine Tumors (NETs) Treatment Revenue Share by Type (2016-2021) Figure 35. China Neuroendocrine Tumors (NETs) Treatment Revenue Growth Rate by Type in 2016 & 2020 Figure 36. China Neuroendocrine Tumors (NETs) Treatment Revenue Share by Application (2016-2021) Figure 37. China Neuroendocrine Tumors (NETs) Treatment Revenue Growth Rate by Application in 2016 & 2020 Figure 38. North America Neuroendocrine Tumors (NETs) Treatment Sales Growth Rate 2016-2021 (K Pcs) Figure 39. North America Neuroendocrine Tumors (NETs) Treatment Revenue Growth Rate 2016-2021 (US$ Million) Figure 40. North America Neuroendocrine Tumors (NETs) Treatment Sales Market Share by Country in 2020 Figure 41. North America Neuroendocrine Tumors (NETs) Treatment Revenue Market Share by Country in 2020 Figure 42. U.S. Neuroendocrine Tumors (NETs) Treatment Sales Growth Rate (2016-2021) (K Pcs) Figure 43. U.S. Neuroendocrine Tumors (NETs) Treatment Revenue Growth Rate (2016-2021) (US$ Million) Figure 44. Canada Neuroendocrine Tumors (NETs) Treatment Sales Growth Rate (2016-2021) (K Pcs) Figure 45. Canada Neuroendocrine Tumors (NETs) Treatment Revenue Growth Rate (2016-2021) (US$ Million) Figure 46. Europe Neuroendocrine Tumors (NETs) Treatment Sales Growth Rate 2016-2021 (K Pcs) Figure 47. Europe Neuroendocrine Tumors (NETs) Treatment Revenue Growth Rate 2016-2021 (US$ Million) Figure 48. Europe Neuroendocrine Tumors (NETs) Treatment Sales Market Share by Country in 2020 Figure 49. Europe Neuroendocrine Tumors (NETs) Treatment Revenue Market Share by Country in 2020 Figure 50. Germany Neuroendocrine Tumors (NETs) Treatment Sales Growth Rate (2016-2021) (K Pcs) Figure 51. Germany Neuroendocrine Tumors (NETs) Treatment Revenue Growth Rate (2016-2021) (US$ Million) Figure 52. France Neuroendocrine Tumors (NETs) Treatment Sales Growth Rate (2016-2021) (K Pcs) Figure 53. France Neuroendocrine Tumors (NETs) Treatment Revenue Growth Rate (2016-2021) (US$ Million) Figure 54. U.K. Neuroendocrine Tumors (NETs) Treatment Sales Growth Rate (2016-2021) (K Pcs) Figure 55. U.K. Neuroendocrine Tumors (NETs) Treatment Revenue Growth Rate (2016-2021) (US$ Million) Figure 56. Italy Neuroendocrine Tumors (NETs) Treatment Sales Growth Rate (2016-2021) (K Pcs) Figure 57. Italy Neuroendocrine Tumors (NETs) Treatment Revenue Growth Rate (2016-2021) (US$ Million) Figure 58. Russia Neuroendocrine Tumors (NETs) Treatment Sales Growth Rate (2016-2021) (K Pcs) Figure 59. Russia Neuroendocrine Tumors (NETs) Treatment Revenue Growth Rate (2016-2021) (US$ Million) Figure 60. Asia Pacific Neuroendocrine Tumors (NETs) Treatment Sales Growth Rate 2016-2021 (K Pcs) Figure 61. Asia Pacific Neuroendocrine Tumors (NETs) Treatment Revenue Growth Rate 2016-2021 (US$ Million) Figure 62. Asia Pacific Neuroendocrine Tumors (NETs) Treatment Sales Market Share by Region in 2020 Figure 63. Asia Pacific Neuroendocrine Tumors (NETs) Treatment Revenue Market Share by Region in 2020 Figure 64. China Neuroendocrine Tumors (NETs) Treatment Sales Growth Rate (2016-2021) (K Pcs) Figure 65. China Neuroendocrine Tumors (NETs) Treatment Revenue Growth Rate (2016-2021) (US$ Million) Figure 66. Japan Neuroendocrine Tumors (NETs) Treatment Sales Growth Rate (2016-2021) (K Pcs) Figure 67. Japan Neuroendocrine Tumors (NETs) Treatment Revenue Growth Rate (2016-2021) (US$ Million) Figure 68. South Korea Neuroendocrine Tumors (NETs) Treatment Sales Growth Rate (2016-2021) (K Pcs) Figure 69. South Korea Neuroendocrine Tumors (NETs) Treatment Revenue Growth Rate (2016-2021) (US$ Million) Figure 70. India Neuroendocrine Tumors (NETs) Treatment Sales Growth Rate (2016-2021) (K Pcs) Figure 71. India Neuroendocrine Tumors (NETs) Treatment Revenue Growth Rate (2016-2021) (US$ Million) Figure 72. Australia Neuroendocrine Tumors (NETs) Treatment Sales Growth Rate (2016-2021) (K Pcs) Figure 73. Australia Neuroendocrine Tumors (NETs) Treatment Revenue Growth Rate (2016-2021) (US$ Million) Figure 74. Taiwan Neuroendocrine Tumors (NETs) Treatment Sales Growth Rate (2016-2021) (K Pcs) Figure 75. Taiwan Neuroendocrine Tumors (NETs) Treatment Revenue Growth Rate (2016-2021) (US$ Million) Figure 76. Indonesia Neuroendocrine Tumors (NETs) Treatment Sales Growth Rate (2016-2021) (K Pcs) Figure 77. Indonesia Neuroendocrine Tumors (NETs) Treatment Revenue Growth Rate (2016-2021) (US$ Million) Figure 78. Thailand Neuroendocrine Tumors (NETs) Treatment Sales Growth Rate (2016-2021) (K Pcs) Figure 79. Thailand Neuroendocrine Tumors (NETs) Treatment Revenue Growth Rate (2016-2021) (US$ Million) Figure 80. Malaysia Neuroendocrine Tumors (NETs) Treatment Sales Growth Rate (2016-2021) (K Pcs) Figure 81. Malaysia Neuroendocrine Tumors (NETs) Treatment Revenue Growth Rate (2016-2021) (US$ Million) Figure 82. Philippines Neuroendocrine Tumors (NETs) Treatment Sales Growth Rate (2016-2021) (K Pcs) Figure 83. Philippines Neuroendocrine Tumors (NETs) Treatment Revenue Growth Rate (2016-2021) (US$ Million) Figure 84. Vietnam Neuroendocrine Tumors (NETs) Treatment Sales Growth Rate (2016-2021) (K Pcs) Figure 85. Vietnam Neuroendocrine Tumors (NETs) Treatment Revenue Growth Rate (2016-2021) (US$ Million) Figure 86. Latin America Neuroendocrine Tumors (NETs) Treatment Sales Growth Rate 2016-2021 (K Pcs) Figure 87. Latin America Neuroendocrine Tumors (NETs) Treatment Revenue Growth Rate 2016-2021 (US$ Million) Figure 88. Latin America Neuroendocrine Tumors (NETs) Treatment Sales Market Share by Country in 2020 Figure 89. Latin America Neuroendocrine Tumors (NETs) Treatment Revenue Market Share by Country in 2020 Figure 90. Mexico Neuroendocrine Tumors (NETs) Treatment Sales Growth Rate (2016-2021) (K Pcs) Figure 91. Mexico Neuroendocrine Tumors (NETs) Treatment Revenue Growth Rate (2016-2021) (US$ Million) Figure 92. Brazil Neuroendocrine Tumors (NETs) Treatment Sales Growth Rate (2016-2021) (K Pcs) Figure 93. Brazil Neuroendocrine Tumors (NETs) Treatment Revenue Growth Rate (2016-2021) (US$ Million) Figure 94. Argentina Neuroendocrine Tumors (NETs) Treatment Sales Growth Rate (2016-2021) (K Pcs) Figure 95. Argentina Neuroendocrine Tumors (NETs) Treatment Revenue Growth Rate (2016-2021) (US$ Million) Figure 96. Middle East and Africa Neuroendocrine Tumors (NETs) Treatment Sales Growth Rate 2016-2021 (K Pcs) Figure 97. Middle East and Africa Neuroendocrine Tumors (NETs) Treatment Revenue Growth Rate 2016-2021 (US$ Million) Figure 98. Middle East and Africa Neuroendocrine Tumors (NETs) Treatment Sales Market Share by Country in 2020 Figure 99. Middle East and Africa Neuroendocrine Tumors (NETs) Treatment Revenue Market Share by Country in 2020 Figure 100. Turkey Neuroendocrine Tumors (NETs) Treatment Sales Growth Rate (2016-2021) (K Pcs) Figure 101. Turkey Neuroendocrine Tumors (NETs) Treatment Revenue Growth Rate (2016-2021) (US$ Million) Figure 102. Saudi Arabia Neuroendocrine Tumors (NETs) Treatment Sales Growth Rate (2016-2021) (K Pcs) Figure 103. Saudi Arabia Neuroendocrine Tumors (NETs) Treatment Revenue Growth Rate (2016-2021) (US$ Million) Figure 104. U.A.E Neuroendocrine Tumors (NETs) Treatment Sales Growth Rate (2016-2021) (K Pcs) Figure 105. U.A.E Neuroendocrine Tumors (NETs) Treatment Revenue Growth Rate (2016-2021) (US$ Million) Figure 106. Neuroendocrine Tumors (NETs) Treatment Value Chain Figure 107. Channels of Distribution Figure 108. Distributors Profiles Figure 109. Bottom-up and Top-down Approaches for This Report Figure 110. Data Triangulation Figure 111. Key Executives Interviewed

Advanced Accelerator Applications AVEO Oncology Boehringer Ingelheim International Hutchison MediPharma Limited IpsenPharma Novartis AG Pfizer, Inc Progenics Pharmaceuticals